Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Nov 27;409(1):5-9.
doi: 10.1016/j.neulet.2006.08.003. Epub 2006 Oct 11.

Tissue transglutaminase crosslinks ataxin-1: possible role in SCA1 pathogenesis

Affiliations

Tissue transglutaminase crosslinks ataxin-1: possible role in SCA1 pathogenesis

D R D'Souza et al. Neurosci Lett. .

Abstract

Transglutaminase type 2 (TG2) has recently been implicated in crosslinking of mutant huntingtin protein into aggregates. Here we show that TG2 also crosslinks spinocerebellar ataxia-1 (SCA1) gene product ataxin-1. HeLa cell lysates expressing GFP tagged ataxin-1 with 2, 30 or 82 glutamines showed covalent crosslinking of ataxin-1 when incubated with exogenously added TG2. This crosslinking was inhibited by TG2 inhibitor cystamine. SCA1 transgenic mice which overexpress the mutant ataxin-1 in cerebellar Purkinje cells showed elevated nuclear TG2 in the absence of ataxin-1 nuclear aggregates. The addition of purified TG2 to the nuclear extracts or addition of SCA1 nuclear TG2 to GFP-Q82 HeLa cell lysates resulted in the formation of insoluble aggregates. These data indicate that ataxin-1 is a substrate of TG2. Further, in SCA1 TG2 may translocate to the nucleus in response to nuclear accumulation of mutant ataxin-1 at early stages of the disease.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Western blots of HeLa cell lysates expressing ataxin-1 (Q2, 30 or 82)-GFP. (A and B) Time course crosslinking of ataxin -1-GFP by TG2. Immunoreactive bands were detected with anti-polyglutamine (A) and anti-GFP (B) antibodies. When indicated, 10 μl aliquots were removed and electrophoresed on a reducing 4–20% polyacrylamide gel. In controls (A) TG2 was omitted except ‘Enz’ (enzyme) lane. The reaction produced large multimers, which stayed on top of the gel. (C) Silver stained gel after 0 and 30 min incubations with TG2. (D and E) GFP immunoblots showing inhibition of ataxin-1 aggregate formation in the presence of various concentrations of TG2 inhibitor cystamine. In ‘E’ the reaction mixtures were incubated for 10 min with guinea pig TG2. Lysate prepared from HeLa cells transfected with GFP without extra Q tract (D) shows no crosslinking.
Fig. 2
Fig. 2
Immunodetection of tissue transglutaminase type 2 (TG2) in cerebellar fractions in SCA1 transgenic and wildtype mice. (A and B) Western blots showing TG2 and calbindin D28k in cerebellar fractions in 4 (n = 4) and 6 (n = 3) weeks old wildtype and SCA1 heterozygous mice. Since calbindin D28k is expressed only in Purkinje cells of the cerebellum we used calbindin as an internal control. As reported previously [17], lower nuclear calbindin levels were observed in SCA1 mice as compared to wildtype animals. On the other hand, elevated levels of nuclear TG2 were seen in SCA1 mice. Figure A also shows altered nuclear and cytosolic distribution of TG2 in 4 weeks old SCA1 mice. TG2 appeared as a single band of about 75 kDa. (C) Immunoblot showing TG2 crosslinked nuclear proteins of 4 weeks old SCA1 and wildtype mice. The insoluble aggregates stayed on top of the gel. The crosslinked proteins were detected with anti-polyglutamine antibody. The reaction was catalyzed by exogenous guinea pig TG2 in the presence and absence of cystamine. (D) Endogenous TG2 in the nuclear fractions crosslinked Hela Q82-GFP (detected with anti-GFP antibody). The nuclear fractions were prepared from the cerebella of 5 weeks old SCA1 homozygous and wildtype mice. Equal amounts of proteins were used in all reactions. In SCA1 mice the intensity of immunoreactive aggregates was markedly higher than the age-matched wildtypes.

References

    1. Aeschlimann D, Tomazy V. Protein crosslinking in assembly and remodeling of extracellular matrices: the role of transglutaminases. Connect Tissue Res. 2000;41:1–27. - PubMed
    1. Bailey CD, Tucholski J, Johnson GV. Transglutaminases in neurodegenerative disorders. Prog Exp Tumor Res. 2005;38:139–157. - PubMed
    1. Burright EN, Clark HB, Servadio A, Matilla T, Feddersen RM, Yunis WS, Duvick LA, Zoghbi HY, Orr HT. SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell. 1995;82:937–948. - PubMed
    1. Gatchel JR, Zoghbi HY. Diseases of unstable repeat expansion: mechanisms and common principles. Nat Rev Genet. 2005;6:743–755. - PubMed
    1. Gentile V, Sepe C, Calvani M, Melone MA, Cotrufo R, Cooper AJ, Blass JP, Peluso G. Tissue transglutaminase-catalyzed formation of high-molecular-weight aggregates in vitro is favored with long polyglutamine domains: a possible mechanism contributing to CAG-triplet diseases. Arch Biochem Biophys. 1998;352:314–321. - PubMed

Publication types

LinkOut - more resources